Jeffrey Saland

Search results

• Alnylam Releases Positive Early Results on Clinical Outcome Measures from ILLuminate-A Phase 3 Study of OXLUMO

  Jeffrey Saland

  6/05/21

  1 item of Media coverage

  Press/Media

• Alnylam announces positive results from phase 3 ILLUMINATE-A study of Oxlumo to treat primary hyperoxaluria type 1

  Jeffrey Saland

  3/05/21 → 5/05/21

  2 items of Media coverage

  Press/Media

• -Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO (lumasiran)

  Jeffrey Saland

  4/05/21

  1 item of Media coverage

  Press/Media

• Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran); - OXLUMO Demonstrated Improvements in Nephrocalcinosis in Patients with Primary Hyperoxaluria Type 1 After 12 Months of Treatment

  Jeffrey Saland

  3/05/21

  1 item of Media coverage

  Press/Media

• US FDA approves Alnylam's Oxlumo to treat primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients

  Jeffrey Saland

  26/11/20

  1 item of Media coverage

  Press/Media

• FDA Approves Oxlumo

  Jeffrey Saland

  25/11/20

  1 item of Media coverage

  Press/Media

• -Alnylam Announces U.S. Food and Drug Administration Approval of OXLUMO, the First and Only Treatment Approved for Primary Hyperoxaluria Type 1

  Jeffrey Saland

  25/11/20

  1 item of Media coverage

  Press/Media

• Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients

  Jeffrey Saland

  24/11/20

  2 items of Media coverage

  Press/Media

• FDA Approves Oxlumo for Primary Hyperoxaluria Type 1

  Jeffrey Saland

  1/11/20

  1 item of Media coverage

  Press/Media

• Alnylam announces positive results from ILLUMINATE-B phase 3 pediatric study of lumasiran to treat hyperoxaluria type 1

  Jeffrey Saland

  24/10/20

  1 item of Media coverage

  Press/Media

• -Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week

  Jeffrey Saland

  23/10/20

  1 item of Media coverage

  Press/Media

• Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week

  Jeffrey Saland

  22/10/20

  3 items of Media coverage

  Press/Media